RxDoctor Payments Data

Kristin Kwong, NP

Family · Torrance, CANPI 1275616393

Payments from drug & device makers

$1,442in general payments, 2019–2025

Across 91 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$739
  • AbbVie$133
  • Aurinia Pharma U.S., Inc.$117
  • Novartis$94
  • Exact Sciences$65
  • Hologic Sales And Service, LLC$47
  • plus $248 from 9 others

What the payments were for

  • Food & beverage$1,27288%
  • Education$17012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,442 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$83,400
Medicare patients
180
Services billed
2,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib27$166,420
Enbrel SureclickEtanercept23$162,558
ProliaDenosumab95$158,522
EnbrelEtanercept20$145,398
Enbrel MiniEtanercept14$106,162
TymlosAbaloparatide11$30,052
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen413$9,677
MethotrexateMethotrexate Sodium212$3,338
Celecoxib63$2,655
Hydroxychloroquine Sulfate73$2,303
Ibandronate Sodium54$1,437
Diclofenac Sodium75$1,265
Duloxetine Hcl55$1,247
Pregabalin42$1,225
Leflunomide23$1,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Enbrel$38$303,920115 claims
AbbVieRinvoq$133$166,42027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →